Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor

Cytotherapy

Volumn 12, Issue 8, 2010, Pages 1044-1055

  Sutlu, Tolga ^a   Stellan, Birgitta ^a   Gilljam, Mari ^a   Quezada, Hernan Concha ^a   Nahi, Hareth ^a   Gahrton, Gösta ^a   Alici, Evren ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

adoptive immunotherapy; ex vivo expansion; good manufacturing practice; natural killer cells; NKp44

Indexed keywords

NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2;

ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; BIOREACTOR; CANCER CELL CULTURE; CELL CULTURE; CELL EXPANSION; CELL FUNCTION; CLINICAL ARTICLE; CYTOTOXICITY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MYELOMA; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 78649303217     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2010.504770     Document Type: Article

References (30)

1. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823-41.
2. Rosenberg S. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst. 1985; 75:595-603.
3. Sutlu T, Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med. 2009;266:154-81.
4. + natural killer cells. Human Immunol. 2001;62:1092-8.
5. Guven H, Gilljam M, Chambers BJ, Ljunggren HG, Christensson B, Kimby E, et al. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy. Leukemia. 2003;17:1973-80.
6. Alici E, Sutlu T, Bjorkstrand B, Gilljam M, Stellan B, Nahi H, et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood. 2008;111:3155-62.
7. Guimaraes F, Guven H, Donati D, Christensson B, Ljunggren HG, Bejarano MT, et al. Evaluation of ex vivo expanded human NK cells on antileukemia activity in SCID-beige mice. Leukemia. 2006;20:833-9.
8. Barkholt L, Alici E, Conrad R, Sutlu T, Gilljam M, Stellan B, et al. Safety analysis of ex vivo expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy. 2009;1:753-64.
9. Miller JS, Klingsporn S, Lund J, Perry EH, Verfaillie C, McGlave P. Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy. Bone Marrow Transplant. 1994;14:555-62.
10. Pierson BA, Europa AF, Hu WS, Miller JS. Production of human natural killer cells for adoptive immunotherapy using a computer-controlled stirred-tank bioreactor. J Hematother. 1996;5:475-83.
11. Luhm J, Brand JM, Koritke P, Hoppner M, Kirchner H, Frohn C. Large-scale generation of natural killer lymphocytes for clinical application. J Hematother Stem Cell Res. 2002;11:651-7.
12. Klingemann HG, Martinson J. Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy. 2004;6:15-22.
13. Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. 2004;24:1861-71.
14. Koehl U, Esser R, Zimmermann S, Tonn T, Kotchetkov R, Bartling T, et al. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klinische Padiatrie. 2005;217:345-50.
15. Torelli GF, Guarini A, Maggio R, Alfieri C, Vitale A, Foa R. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission. Haematologica. 2005;90:785-92.
16. Ruggeri L, Mancusi A, Capanni M, Martelli MF, Velardi A. Exploitation of alloreactive NK cells in adoptive immuno-therapy of cancer. Curr Opin Immunol. 2005;17:211-7.
17. Frohn C, Doehn C, Durek C, Bohle A, Schlenke P, Jocham D, et al. Feasibility of the adoptive transfusion of allogenic human leukocyte antigen-matched natural killer cells in patients with renal cell carcinoma. J Immunother. 2000;23:499-504.
18. Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kuhne T, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia. 2004;18:1835 - 8.
19. Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, et al. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autolo-gous natural killer cells: a clinical phase I trial. Clin Cancer Res. 2004;10:3699-707.
20. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051-7.
21. Heiskala MK, Carpen O, Saksela E, Timonen T. Mechanism of cell contact-mediated inhibition of natural killer activity. J Immunol. 1987;139:1414-8.
22. Ramsdell FJ, Golub SH. Generation of lymphokine-activated killer cell activity from human thymocytes. J Immunol. 1987; 139:1446-53.
23. Chan JK, Hamilton CA, Cheung MK, Karimi M, Baker J, Gall JM, et al. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bis-pecific antibodies: a preclinical study. Clin Cancer Res. 2006; 12:1859-67.
24. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994;153:1687-96.
25. Bordignon C, Carlo-Stella C, Colombo MP, De Vincentiis A, Lanata L, Lemoli RM, et al. Cell therapy: achievements and perspectives. Haematologica. 1999;84:1110-49.
26. Khalil-Daher I, Riteau B, Menier C, Sedlik C, Paul P, Dausset J, et al. Role of HLA-G versus HLA-E on NK function: HLA-G is able to inhibit NK cytolysis by itself. J Reprod Immunol. 1999;43:175-82.
27. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med. 1998;187:2065-72.
28. Biassoni R, Bottino C, Cantoni C, Moretta A. Human natural killer receptors and their ligands. Curr Protoc Immunol. 2002; 14:10.
29. LaIuppa JA, McAdams TA, Papoutsakis ET, Mller WM. Culture materials affect ex vivo expansion of hematopoietic progenitor cells. J Biomed Mater Res. 1997;36:347-59.
30. Nielsen LK. Bioreactors for hematopoietic cell culture. Annu Rev Biomed Eng. 1999;1:129-52.